Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

Tetyana Bagnyukova, Ilya G. Serebriiskii, Yan Zhou, Elizabeth A. Hopper-Borge, Erica A. Golemis, Igor Astsaturov

Research output: Contribution to journalReview articlepeer-review

79 Scopus citations


In recent years, oncologists have begun to conclude that chemotherapy has reached a plateau of efficacy as a primary treatment modality, even if toxicity can be effectively controlled. emerging specific inhibitors of signaling and metabolic pathways (i.e., targeted agents) contrast with traditional chemotherapy drugs in that the latter primarily interfere with the DNA biosynthesis and the cell replication machinery. in an attempt to improve on the efficacy, combination of targeted drugs with conventional chemotherapeutics has become a routine way of testing multiple new agents in early phase clinical trials. This review discusses the recent advances including integrative systematic biology and RNAi approaches to counteract the chemotherapy resistance and to buttress the selectivity, efficacy and personalization of anticancer drug therapy.

Original languageEnglish
Pages (from-to)839-853
Number of pages15
JournalCancer Biology and Therapy
Issue number9
StatePublished - Nov 1 2010


  • Antineoplastic Agents/pharmacology
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Cell Death
  • Chemotherapy, Adjuvant
  • Drug Resistance, Neoplasm
  • Humans
  • Intracellular Signaling Peptides and Proteins/metabolism
  • Microtubules/drug effects
  • Molecular Targeted Therapy
  • Neoplasms/drug therapy
  • Protein Kinases/metabolism
  • RNA Interference
  • Signal Transduction/drug effects


Dive into the research topics of 'Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?'. Together they form a unique fingerprint.

Cite this